Novavax beats first-quarter revenue estimates on vaccine deals strength
06/05/2026 12:55
May 6 (Reuters) - Novavax NVAX.O on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine supply and licensing deals helped offset pressure from sagging demand. First-quarter revenue came in at $139.5 million, topping analysts' estimate of $78.3 million, according to LSEG-compiled data. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Devika Syamnath) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Novavax
See all newsNovavax shareholder Shah Capital to step back from activist role
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects
Brief: Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season
US FDA approves updated COVID vaccines for 2026-27 season
US STOCKS-Wall St rises as yields ease, Moderna lifts healthcare stocks